Published in Cancer Vaccine Week, October 4th, 2004
"Clinical outcomes were evaluated in 89 consecutive patients with multiple myeloma that had not responded to dexamethasone-based primary therapy and who had received early intensive therapy supported by autologous stem cell transplantation.
"Results were compared with those of 45 comparable patients who refused or were unable to receive intensive treatment for socioeconomic reasons," scientists in the United States report.
"Following high-dose therapy," wrote R. Alexanian and coworkers, "the response rate was 69% including 16% with CR. Survival of 14...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.